We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Oligodendrocyte transcription factor 2 phosphoS147 (OLIG2 pS147) antibody
Oligodendrocyte transcription factor 2, Oligo2
Class B basic helix-loop-helix protein 1, bHLHb1
Class E basic helix-loop-helix protein 19, bHLHe19
Protein kinase C-binding protein 2
Protein kinase C-binding protein RACK17
Gene name: OLIG2, BHLHB1, BHLHE19, PRKCBP2, RACK17
Class B basic helix-loop-helix protein 1, bHLHb1
Class E basic helix-loop-helix protein 19, bHLHe19
Protein kinase C-binding protein 2
Protein kinase C-binding protein RACK17
Gene name: OLIG2, BHLHB1, BHLHE19, PRKCBP2, RACK17
As low as
$306.10
In stock
Ref
00013758
Oligodendrocyte transcription factor 2 phosphoS147 (OLIG2 pS147) antibody
| ID Covalab | pab0754 |
|---|---|
| Product type | Primary antibodies |
| Clonality | Polyclonal antibody |
| Raised in | Rabbit |
| Immunogen | Synthetic peptide containing phospho Serine147 derived frominternal domain of human OLIG 3. |
| Activity cross reaction | Reacts with human 29 kDa phosphoprotein. May cross-reacts with OLIG2 pS147 from mouse and with mouse OLIG2, bHLHB3, 4, 5 and also nHLHB7 from other species. |
| Species | Hu |
| Labelling | None |
| Form | Antiserum |
| Preservative | None |
| Storage instructions | Lyophilized powder stable for a minimum of 2 years at -20°C. Store reconstituted antibodies at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt. |
| Target | Oligodendrocyte transcription factor 2 phosphoS147 (OLIG2 pS147) |
| Uniprot ID | Q13516 |
| Gene ID | 10215 |
| Applications | ELISA, IHC, WB |
| Working dilutions | Optimal dilution should be determined by the end user. The following are guidelines only: WB (1:200 - 1:2000) IHC (1:50 - 1:500) |
| Publication | * Li H, et al. Phosphorylation regulates OLIG2 cofactor choice and the motor neuron-oligodendrocyte fate switch. Neuron. 2011 Mar 10,69(5):918-29. |
Write Your Own Review